Viyash Scientific Limited share price
NSE: VIYASH · ISIN INE807F01027
Key numbers
- Market cap
- ₹ 10,781 Cr
- Current price
- ₹ 244.35
- 52-week high / low
- ₹ 298 / 178
- Stock P/E
- 51.4
- Book value
- ₹ 66.7
- Dividend yield
- 0.00%
- ROCE
- 12.7%
- ROE
- 6.6%
- Debt to equity
- 0.17
- Sales growth (3 yrs)
- 33.3%
- Profit growth (3 yrs)
- -
- 1-year return
- 23.7%
About Viyash Scientific Limited
Viyash Scientific Limited operates as a veterinary pharmaceutical Company in India, the United States, Spain, and internationally. The company provides active pharmaceutical ingredients, finished dosage formulations, analytical services, and VET formulation services for cattle and poultry. The company was formerly known as Sequent Scientific Limited and changed its name to Viyash Scientific Limited in January 2026. The company was incorporated in 1985 and is headquartered in Hyderabad, India. Viyash Scientific Limited operates as a subsidiary of CA Harbor Investments.
Quarterly results
Consolidated figures in ₹ crores
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 792 | 424 | 858 | 920 | 946 |
| Operating profit | 115 | 56 | 176 | 188 | 180 |
| Net profit | 32 | 15 | 38 | 52 | 66 |
| EPS (₹) | 0.74 | 0.59 | 0.89 | 1.20 | 1.51 |
Concall summary (2026-08-16)
AI summary of the earnings call transcript · tone: Positive · source document
Guidance & outlook
- So, next year it's going to be flat, small maybe after completing this 1.3 crores.
- So, this year we can expect at mid-teens, 13%-15% kind of thing together.
Growth & demand
- Our Animal Health Formulation business continues to grow very strong across all regions, and we believe the growth will continue with our continuous focus on new product launches, geo - extension for our existing products to other countries, expanding R&D and accelerating new product development.
- But by and large, we are growing volume over there and the volume growth in that market plus the pricing growth should get us back to the levels at which we have typically been which would be in the close to that 18-20% growth.
Margins & costs
- 205 crores, grown by 59% year -on-year, with EBITDA margin at 21.6%, expanding by almost 530 basis points over last year.
- So, to summarize: Q1 FY'27 shows continuity, sustained double -digit revenue growth, EBITDA margins around 20%-22% as indicated earlier, balance sheet now strongest ever in the history.
Capex & expansion
- This gives us tremendous opportunity with respect to brownfield expansion as well as exploring inorganic opportunities.
- Coming to where we are investing for growth: We have signed SPA for Bio For Life acquisition in Italy, and we are expecting to close the acquisition in next few months basis fulfillment of certain conditions as per the agreement.
Balance sheet & cash
- 86 crores and net debt to EBITDA is now 0.1x versus 0.24x last quarter, and almost 1x a year back.
- So, in 4 quarters, we have gone from a leveraged combined entity to a company which is virtually debt- free on a net basis.
Peers in Drug Manufacturers - Specialty & Generic
Data for information only, not investment advice. Prices end of day.